Sanofi (SNY)
After hours:
| Previous close | 44.93 |
| Open | 45.11 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 900 |
| Day's range | 44.48 - 49.75 |
| 52-week range | 36.91 - 58.10 |
| Volume | |
| Avg. volume | 2,794,691 |
| Market cap | 124.842B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 18.05 |
| EPS (TTM) | 2.69 |
| Earnings date | N/A |
| Forward dividend & yield | 1.75 (3.89%) |
| Ex-dividend date | 26 May 2022 |
| 1y target est | 58.50 |
- Motley Fool
These 3 Stocks Escaped Tuesday's Market Downdraft
Even a dour outlook for the broader stock market couldn't outweigh good news for these companies.
- Financial Times
US judge rules for pharma groups in cancer litigation over Zantac
A US judge has dismissed thousands of lawsuits claiming that popular heartburn medication Zantac causes cancer, handing a big victory to pharmaceutical companies GSK, Pfizer, Sanofi and Boehringer Ingelheim. US District Judge Robin Rosenberg in West Palm Beach, Florida, said in an order on Tuesday that the almost 2,500 lawsuits filed in federal court by plaintiffs were based on flawed science, and that the only reliable testing of the blockbuster drug undertaken showed an “unprovable risk of cancer”.
- Motley Fool
Why Shares of Provention Bio Went Up 30.3% in November
Shares of Provention Bio (NASDAQ: PRVB) rose 30.3% in November, according to data from S&P Global Intelligence. The pharmaceutical company closed out October at $6.94 and opened November at $7. The move up can be directly tied to the approval of Provention therapy Tzield (teplizumab-mzwv) by the Food and Drug Administration (FDA) on Nov. 17.
